UP!
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates (FABACs). Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis (NASH), a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance.
Galmed Pharmaceuticals, in its current legal structure, was incorporated in Israel on July 31, 2013 as a privately held company. However, Galmed’s business has been operating since 2000 under a different group of companies established in the same year. Galmed was co-founded by Professor Tuvia Gilat and Allen Baharaff, based on Professor Gilat’s extensive research in FABACs and NASH.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2023 | 2022-11-07 | Future report Set alerts | |
| Q2 2023 | 2022-08-04 | -0.15 | -0.15 |
| Q1 2023 | 2022-05-17 | -0.24 | -0.24 |
| Q4 2022 | 2022-05-02 | -0.30 | -0.30 |
| Q1 2022 | 2022-04-22 | 0.00 | 0.00 |
| Q4 2021 | 2022-03-21 | 0.00 | 0.00 |
| Q3 2021 | 2021-11-08 | -0.31 | -0.31 |
| Q2 2021 | 2021-08-05 | 0.33 | 0.33 |
| Q1 2021 | 2021-05-13 | -0.38 | -0.38 |
| Q4 2020 | 2021-03-18 | -0.48 | -0.48 |
| 2016-07-06 | Reiterated Rating | Roth Capital | Buy | $6.00 |
| 2016-06-30 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-06-08 | Reiterated Rating | Maxim Group | Buy | |
| 2016-06-02 | Reiterated Rating | Maxim Group | Buy | |
| 2016-05-16 | Reiterated Rating | Maxim Group | Buy | |
| 2016-05-04 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-05-04 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-05-04 | Reiterated Rating | FBR & Co | Buy | |
| 2016-05-03 | Reiterated Rating | Maxim Group | Buy | |
| 2016-03-28 | Initiated Coverage | HC Wainwright | Buy | $22.00 |
| 2016-03-24 | Reiterated Rating | FBR & Co. | Buy | $20.00 |
| 2016-03-07 | Reiterated Rating | HC Wainwright | Buy | $21.00 |
| 2016-03-01 | Reiterated Rating | Maxim Group | Buy | $24.00 |
| 2016-02-14 | Initiated Coverage | Maxim Group | Buy | |
| 2015-10-30 | Reiterated Rating | FBR & Co. | Outperform | |
| 2015-08-19 | Reiterated Rating | MLV & Co. | Buy | $24.00 |
| 2015-08-14 | Lower Price Target | SunTrust | Buy | $20.00 to $19.00 |
| 2015-08-14 | Lower Price Target | SunTrust Banks Inc. | Buy | $20.00 to $19.00 |
| 2015-08-13 | Reiterated Rating | Roth Capital | Buy | |
| 2015-08-13 | Reiterated Rating | Maxim Group | Buy | $24.00 |
| 2015-07-09 | Reiterated Rating | Roth Capital | Buy | $20.00 |
| 2015-07-08 | Reiterated Rating | Maxim Group | Buy | $24.00 |
| 2015-06-23 | Initiated Coverage | HC Wainwright | Buy | $21.00 |
| 2015-05-15 | Reiterated Rating | Maxim Group | Buy | $24.00 |
| 2015-05-06 | Initiated Coverage | SunTrust | Buy | $20.00 |
| 2015-04-15 | Initiated Coverage | Roth Capital | Buy | $20.00 |
| 2015-04-01 | Reiterated Rating | MLV & Co. | Buy | $24.00 |
| 2015-03-27 | Reiterated Rating | Maxim Group | Buy | $24.00 |
| 2015-03-09 | Reiterated Rating | MLV & Co. | Buy | $24.00 |
| 2014-09-24 | Reiterated | MLV & Co | Buy | $19 to $24 |
| 2014-09-24 | Boost Price Target | MLV & Co. | Buy | $19.00 to $24.00 |
| 2014-05-09 | Initiated Coverage | MLV & Co. | Buy | $19.00 |
| 2014-04-23 | Initiated Coverage | Maxim Group | Buy | $24.00 |
| 2016-07-06 | Reiterated Rating | Roth Capital | Buy | $6.00 |
| 2016-06-30 | Reiterated Rating | HC Wainwright | Buy | |
| 2016-06-08 | Reiterated Rating | Maxim Group | Buy | |
| 2016-06-02 | Reiterated Rating | Maxim Group | Buy | |
| 2016-05-16 | Reiterated Rating | Maxim Group | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In GLMD 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
UM